|Grant ID: RR160080|
Recruitment of First-Time, Tenure-Track Faculty Members
Dana-Farber Cancer Institute/Harvard Medical School
September 14, 2016
Non-small–cell lung cancer is the leading cause of death from cancer in the U.S. Immune therapy is providing some patients with essentially a cure for their disease, but a majority of patients don’t respond to immune therapy at all. Predicting which patients can benefit from immune therapy isn’t yet possible. But a researcher now at The University of Texas Southwestern Medical Center hopes to be able to provide some insight.
Cancer biologist Esra Akbay was recruited to the Department of Pathology and Simmons Comprehensive Cancer Center from Dana-Farber Cancer Institute in 2016 with the help of a First-Time Tenure-Track Award from CPRIT. Akbay returns to her Ph.D. alma mater.